A Phase 3 interventional study of Teduglutide in Short Bowel Syndrome, sponsored by Shire. Completed at 5 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 13th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 9th registered.
159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.
Browse Short Bowel Syndrome studies →1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 4 mo–17 yrs
By country, each count listing its studies:
teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2014.
This study's enrollment of 11 is below the median of 21 across 108 interventional studies indexed under Short Bowel Syndrome.
Median enrollment 20 across the 20 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 20 have an industry lead sponsor. The 6 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
26 studies in Short Bowel Syndrome by Takeda: 1 open now, 3 under way, 1 of them phase 3. Of 23 finished, 16 (70%) have results posted.
Among the 26 studies in Short Bowel Syndrome by Takeda, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2014, is one of 17 in phase 3, and was the 9th registered.
Takeda’s Short Bowel Syndrome studies by the year they started, since 2004.
1 of the studies testing teduglutide in Short Bowel Syndrome that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973304Phase 3TakedaA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing teduglutide in Short Bowel Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 26 in Short Bowel Syndrome:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of an investigational treatment (teduglutide) in Japanese patients with PN-dependent SBS. This study will also look at how teduglutide moves through the body (pharmacokinetics).
This study has 3 stages, consisting of an optimization/stabilization period (Stage 1), a 24-week treatment period in which all patients will receive teduglutide (Stage 2), and a long-term extension (Stage 3).
During the long-term extension (Stage 3), patients will continue to receive teduglutide for up to an additional 24 months or until teduglutide is commercially available, whichever comes earlier.
0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
Drug: Teduglutide
0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Absolute change from baseline in weekly PS volume at Week 24 was reported.
Time frame: Baseline (stage 2), Week 24
Stage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24
Percent change from baseline in weekly PS volume at Week 24 was reported.
Time frame: Baseline (stage 2), Week 24
Stage 2: Percentage of Participants Who Demonstrate Response to Teduglutide at End of Stage 2
Response was defined as the achievement of at least a 20% reduction from baseline (Visit 2) in weekly PS volume at Week 20 and again at Week 24.
Time frame: End of Stage 2 (up to Week 24)
Stage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24
Absolute change from baseline in number of days per Week of PS usage at Week 24 was reported.
Time frame: Baseline (stage 2), Week 24
Stage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 24
Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at Week 24 was reported.
Time frame: Baseline (stage 2), Week 24
Stage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 24
Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at Week 24 was reported.
Time frame: Baseline (stage 2), Week 24
Stage 2: Number of Participants Who Achieved Enteral Autonomy at Week 24
Enteral autonomy was defined as no prescribed PS and no use of PS recorded in the participant diary at the end of stage 2. Number of participants who achieved enteral autonomy at Week 24 was reported.
Time frame: Week 24
Stage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24
Absolute change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
Time frame: Baseline (stage 3), Extension Month 24
Stage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24
Percent change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
Time frame: Baseline (stage 3), Extension Month 24
Stage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24
Absolute change from baseline in number of days per Week of PS usage at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
Time frame: Baseline (stage 3), Extension Month 24
Stage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 24
Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
Time frame: Baseline (stage 3), Extension Month 24
Stage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24
Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
Time frame: Baseline (stage 3), Extension Month 24
Stage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment
Absolute change from baseline in weekly PS volume at end of treatment was reported.
Time frame: Baseline (stage 4), End of Treatment (up to 47 months)
Stage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment
Percent change from baseline in weekly PS volume at end of treatment was reported.
Time frame: Baseline (stage 4), End of Treatment (up to 47 months)
Stage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment
Absolute change from baseline in number of days per week of PS usage at end of treatment was reported.
Time frame: Baseline (stage 4), End of Treatment (up to 47 months)
Stage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment
Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at end of treatment was reported.
Time frame: Baseline (stage 4), End of Treatment (up to 47 months)
Stage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment
Plasma citrulline was measured as an assessment of enterocyte mass. Percent change in plasma citrulline from baseline at end of treatment was reported.
Time frame: Baseline (stage 4), End of Treatment (up to 47 months)
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma
Area under the concentration-time curve from time zero to infinity of teduglutide in plasma were evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Area Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma
Area under the concentration-time curve from time zero to the last time point of teduglutide in plasma were evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Maximum Concentration (Cmax) of Teduglutide in Plasma
Maximum concentration of teduglutide in plasma were evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma
Time to reach maximum observed drug concentration of teduglutide in plasma was evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Terminal Half-Life (t1/2) of Teduglutide in Plasma
Terminal half-life of teduglutide in plasma were evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Apparent Clearance (CL/F) of Teduglutide in Plasma
Apparent clearance of teduglutide in plasma were evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
Apparent Volume of Distribution (Vz/F) of Teduglutide in Plasma
Apparent volume of distribution of teduglutide in plasma were evaluated.
Time frame: Pre-dose, 15, 30, 60 minutes, 2, 3, 4, 6, 8, 10 and 12 hours post-dose
The study was conducted at five centers in Japan between 18 December 2014 (first participant first visit) and 12 November 2018 (last participant last visit).
| Milestone | Teduglutide |
|---|---|
| Started | 11 |
| Started stage 2 | 11 |
| Completed stage 2 | 9 |
| Started stage 3 | 8 |
| Completed stage 3 | 7 |
| Started stage 4 | 7 |
| Completed stage 4 | 7 |
| Completed | 7 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Discontinued with other reason | 1 |
Absolute change from baseline in weekly PS volume at Week 24 was reported.
| Liter per week (L/week) | Teduglutide |
|---|---|
| Stage 2: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 | -4.92 ± 4.749 |
Percent change from baseline in weekly PS volume at Week 24 was reported.
| Percent change in PS volume | Teduglutide |
|---|---|
| Stage 2: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Week 24 | -30.07 ± 25.892 |
Response was defined as the achievement of at least a 20% reduction from baseline (Visit 2) in weekly PS volume at Week 20 and again at Week 24.
| Percentage of Participants | Teduglutide |
|---|---|
| PS Response: Yes | 45.5 |
| PS Response: No | 54.5 |
Absolute change from baseline in number of days per Week of PS usage at Week 24 was reported.
| Days per week (days/week) | Teduglutide |
|---|---|
| Stage 2: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Week 24 | -1.0 ± 1.80 |
Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at Week 24 was reported.
| Micromoles per liter | Teduglutide |
|---|---|
| Stage 2: Absolute Change From Baseline in Plasma Citrulline Levels at Week 24 | 15.0 ± 17.37 |
Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at Week 24 was reported.
| Percent change | Teduglutide |
|---|---|
| Stage 2: Percent Change From Baseline in Plasma Citrulline Levels at Week 24 | 86.9 ± 112.33 |
Enteral autonomy was defined as no prescribed PS and no use of PS recorded in the participant diary at the end of stage 2. Number of participants who achieved enteral autonomy at Week 24 was reported.
| Participants | Teduglutide |
|---|---|
| Stage 2: Number of Participants Who Achieved Enteral Autonomy at Week 24 | 0 |
Absolute change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
| L/week | Teduglutide |
|---|---|
| Stage 3: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24 | -8.33 ± 5.940 |
Percent change from baseline in weekly PS volume at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
| Percent change in PS volume | Teduglutide |
|---|---|
| Stage 3: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at Extension Month 24 | -53.53 ± 33.866 |
Absolute change from baseline in number of days per Week of PS usage at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
| days/week | Teduglutide |
|---|---|
| Stage 3: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at Extension Month 24 | -2.1 ± 3.34 |
Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
| Micromoles per liter | Teduglutide |
|---|---|
| Stage 3: Absolute Change From Baseline in Plasma Citrulline Levels at Extension Month 24 | 28.3 ± 24.05 |
Plasma citrulline was measured as an assessment of enterocyte mass. Percent change from baseline in plasma citrulline at extension Month 24 was reported. Extension month 24 = 30 months of teduglutide treatment.
| Percent change | Teduglutide |
|---|---|
| Stage 3: Percent Change From Baseline in Plasma Citrulline Levels at Extension Month 24 | 135.0 ± 84.17 |
Absolute change from baseline in weekly PS volume at end of treatment was reported.
| L/week | Teduglutide |
|---|---|
| Stage 4: Absolute Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment | -5.08 ± 6.404 |
Percent change from baseline in weekly PS volume at end of treatment was reported.
| Percent change in PS volume | Teduglutide |
|---|---|
| Stage 4: Percent Change From Baseline in Weekly Parenteral Support (PS) Volume at End of Treatment | -34.12 ± 38.877 |
Absolute change from baseline in number of days per week of PS usage at end of treatment was reported.
| days/week | Teduglutide |
|---|---|
| Stage 4: Absolute Change From Baseline in Number of Days Per Week of Parenteral Support (PS) Usage at End of Treatment | -1.4 ± 2.80 |
Plasma citrulline was measured as an assessment of enterocyte mass. Absolute change from baseline in plasma citrulline levels at end of treatment was reported.
| Micromoles per liter | Teduglutide |
|---|---|
| Stage 4: Absolute Change From Baseline in Plasma Citrulline Levels at End of Treatment | 19.3 ± 19.96 |
Plasma citrulline was measured as an assessment of enterocyte mass. Percent change in plasma citrulline from baseline at end of treatment was reported.
| Percent change | Teduglutide |
|---|---|
| Stage 4: Percent Change From Baseline in Plasma Citrulline Levels at End of Treatment | 110.3 ± 98.13 |
Area under the concentration-time curve from time zero to infinity of teduglutide in plasma were evaluated.
| Nanogram*hour per milliliter (ng*h/mL) | Teduglutide |
|---|---|
| Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-Inf) of Teduglutide in Plasma | 204 ± 51.1 |
Area under the concentration-time curve from time zero to the last time point of teduglutide in plasma were evaluated.
| ng*h/mL | Teduglutide |
|---|---|
| Area Under the Concentration-Time Curve From Time Zero to the Last Time Point (AUC0-t) of Teduglutide in Plasma | 201 ± 51.6 |
Maximum concentration of teduglutide in plasma were evaluated.
| Nanogram per milliliter (ng/mL) | Teduglutide |
|---|---|
| Maximum Concentration (Cmax) of Teduglutide in Plasma | 49.7 ± 19.7 |
Time to reach maximum observed drug concentration of teduglutide in plasma was evaluated.
| hour | Teduglutide |
|---|---|
| Time to Reach Maximum Observed Drug Concentration (Tmax) of Teduglutide in Plasma | 2.49 (1.17 to 4.00) |
Terminal half-life of teduglutide in plasma were evaluated.
| hour | Teduglutide |
|---|---|
| Terminal Half-Life (t1/2) of Teduglutide in Plasma | 1.06 (0.62 to 2.63) |
Apparent clearance of teduglutide in plasma were evaluated.
| liter per hour (L/h) | Teduglutide |
|---|---|
| Apparent Clearance (CL/F) of Teduglutide in Plasma | 14.5 ± 4.09 |
Apparent volume of distribution of teduglutide in plasma were evaluated.
| liter | Teduglutide |
|---|---|
| Apparent Volume of Distribution (Vz/F) of Teduglutide in Plasma | 27.8 ± 22.5 |
Collected over From start of study treatment up to end of the study (up to 47 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teduglutide | 1/11 (9.1%) | 7/11 (63.6%) | 11/11 (100%) |
| Event | Teduglutide |
|---|---|
| Device related infectionInfections and infestations | 7/11 |
| ThrombophlebitisVascular disorders | 1/11 |
| EnteritisGastrointestinal disorders | 1/11 |
| EnterocolitisGastrointestinal disorders | 1/11 |
| Intestinal obstructionGastrointestinal disorders | 1/11 |
| Device occlusionGeneral disorders | 1/11 |
| PyrexiaGeneral disorders | 1/11 |
| Arthritis bacterialInfections and infestations | 1/11 |
| Catheter site infectionInfections and infestations | 1/11 |
| SepsisInfections and infestations | 1/11 |
| Event | Teduglutide |
|---|---|
| HeadacheNervous system disorders | 6/11 |
| PyrexiaGeneral disorders | 5/11 |
| NasopharyngitisInfections and infestations | 5/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/11 |
| Abdominal painGastrointestinal disorders | 4/11 |
| Abdominal distensionGastrointestinal disorders | 3/11 |
| DiarrhoeaGastrointestinal disorders | 3/11 |
| NauseaGastrointestinal disorders | 3/11 |
| StomatitisGastrointestinal disorders | 3/11 |
| VomitingGastrointestinal disorders | 3/11 |
Safety population consisted of all participants in the intent-to-treat (ITT) population who received at least one dose of study drug. ITT population consists of all participants who are enrolled and eligible to enter Stage 2.
| Age, Continuous(Years) | Teduglutide |
|---|---|
| Mean | 40.9 ± 12.41 |
| Sex: Female, Male(Participants) | Teduglutide |
|---|---|
| Female | 3 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Teduglutide |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 11 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Teduglutide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the limited number of study participants/study sites, ...)
Ran from Dec 2014 to primary completion in Nov 2018, 46 months.
Results were first posted in Nov 2019, 1 year after primary completion.
Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 46 months is above that.
Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teduglutide